MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ALLR had -$1,100K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$1,100K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-2,806 -5,052
Depreciation and amortization
-21 -
Common stock issued for services
-50 -50
Stock-based compensation
132 303
Impairment of intangible assets
0 -
Unrealized foreign exchange gains
0 13
Non-cash interest expense
74 92
Depreciation and amortization
-23
Change in fair value of warrant and derivative liabilities
0 -1
Deferred income taxes
0 0
Other current assets
-3 1
Tax credit receivable
53 839
Prepaid expenses
439 850
Accounts payable
-3 436
Accrued expenses and other liabilities
-324 -2,322
Income taxes payable
0 7
Net cash used in operating activities
-3,410 -8,167
Proceeds from atm sales of common stock, net of issuance costs
0 11,143
Net proceeds from sale of common stock and pre-funded warrant issuance
2,451 -
Proceeds from issuance of convertible redeemable series a preferred stock
0 -
Redemption of convertible redeemable series a preferred stock
0 -
Proceeds from convertible promissory notes and accrued interest, net of discount
0 0
Repayment of debt and promissory notes
0 0
Common stock repurchase
141 2,565
Net cash provided by financing activities
2,310 8,578
Net increase in cash and cash equivalents
-1,100 411
Effect of exchange rate changes on cash
-1,949 -
Cash and cash equivalents at beginning of period
19,533 -
Cash and cash equivalents at end of period
16,895 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics, Inc. (ALLR)